BioSpace News Archive

RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release announcing receipt of the U.S. Food and Drug Administration’s response to NRx’s October 8, 2021 submission of updated manufacturing information for aviptadil.

Angion Biomedica Corp, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, provided a corporate update and reported financial results for the quarter ended September 30, 2021.

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC).

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced updated interim data from the Phase 1 data from RP2 alone and in combination with Opdivo that continues to provide strong support for the next stage development of RP2.

BD, a leading global medical technology company, will begin its Investor Day at 8 a.m. ET to share how it plans to leverage the breadth and depth of its core portfolio to fuel a new wave of growth through transformative solutions that can help reinvent health care.

Nordic Nanovector ASA announces that it will report its results for the third quarter 2021 on Thursday, 18 November 2021.

Nanoform, an innovative nanoparticle medicine enabling company, announced it has received ISO/IEC 27001:2013 certification for its Information Security Management System.